Degradation of type I and II collagen by human C1&#x0304;s  by Yamaguchi, Kiichiro et al.
Volume 268, number 1, 206-208 FEBS 08698 July 1990 
Degradation of type I and II collagen by human Cis 
Kiichiro Yamaguchil, Hisako Sakiyama2, Misako MatsumoW, Hideshige Moriya3 and 
Shigeru Sakiyama4 
‘Division of Physiology and Pathology, National Institute of Radiological Sciences, 4-9-l Anagawa, Chiba 260, Japan, 2The 
Department of Immunology, The Center for Adult Diseases, Osaka, Higashinari-ku, Osaka 537, Japan, 3 The Department of 
Orthopaedics, Chiba University School of Medicine, 1-8-I Inohana, Chiba 280, Japan and 4Division of Biochemistry, Chiba Cancer 
Center, Research Institute, 666-2 Nitona, Chiba 280, Japan 
Received 5 June 1990 
The activated first component of human complement, Cis, was shown to cleave type I and II collagen and gelatin. The proteolytic activity was 
heat labile and was inhibited by a monoclonal antibody (M241) which recognized light chain of active human Cls or by a serine protease inhibitor, 
DFP, but not by a chelating agent. 
Cis; Collagen type I; Collagen type II 
1. INTRODUCTION 
We have purified a calcium-dependent serine pro- 
teinase (CASP) from the conditioned medium of 
hamster embryo fibroblasts, Ni12C2 cells [l] with high 
metastatic and phagocytotic activities [2]. CASP had 
been shown to degrade several components of ex- 
tracellular matrix. Nucleotide sequence of the com- 
plementary DNA of CASP [3] was found to have a 
homology with that of human Cls, whose complete 
nucleotide sequence was reported in several studies 
[4-61. We also found that CASP cleaved human C2 
and C4 to form C3 convertase. Monoclonal antibodies 
against human Cls recognized CASP and the converse 
was the case [7]. Moreover, an immunohistochemical 
examination of CASP revealed that chondrocytes of 
hyaline cartilage were highly reactive to a monoclonal 
antibody against CASP [B]. Therefore, we decided to 
investigate the proteolytic activity of activated human 
C 1 s (Cls) towards extracellular matrix proteins such as 
collagen and fibronectin, which had been shown to be 
cleaved by CASP [l]. 
2. MATERIALS AND METHODS 
2.1. Purification of human C?s 
Cls was purified as described by Gigli [9] with modifications [lo]. 
Correspondence address: H. Sakiyama, Division of Physiology and 
Pathology, National Institute of Radiological Sciences, 4-9-l 
Anagawa, Chiba 260, Japan 
Abbreviations: CASP, calcium-dependent serine proteinase; 
AGLNE, acetyl-Gly-L-Lys-naphthyl ester; DFP, diisopropyl 
fluorophosphate 
Briefly, 1 vol. of fresh human serum was added to 4 vols of distilled 
water containing 5 mM CaCla (pH 7.4). The precipitate was 
resuspended in 10 mM Tris-HCl buffer (pH 8.0) containing 0.5 M 
NaCl and 5 mM CaClz, and applied on Sepharose 6B column. The 
fractions with Cl hemolytic activity were then separated on a DEAE- 
Sephadex A-50 column with a linear gradient of NaCl(O.l5-0.25 M) 
in 10 mM Tris-HCl buffer (pH 7.8). Cls was finally purified with 
Sephadex G-200 column. 
2.2. Preparation of monoclonal antibody against human C?s 
A monoclonal antibody against human Cis was obtained by im- 
munizing (BALB/c x C57BL/6) Fi mice with purified human Cis as 
reported before [lo]. Clones were screened for the ability to inhibit 
Cls activity by microplate hemolytic ELISA assay. An antibody, 
M241, which recognized the activated form of Cls but not the in- 
active one [lo] was used in the present study. 
2.3. Proteolytic assay of human Cis 
Fivepg of type 1 (Vitrogen 100, Flow Lab., VA), mouse type II col- 
lagen, gelatin (Sigma Co., MO), fibronectin (Extraco Nobel Indust., 
Sweden) or laminin were incubated with 1 pM human Cls at 37°C 
overnight in 20~1 of 100 mM Tris-HCl buffer (pH 7.4) containing 
100 mM NaCl and 5 mM CaCl2. To examine effects of monoclonal 
antibody (M241), diisopropyl fluorophosphate (DFP) (Sigma Co., 
MO) or EDTA on the proteolytic activity, the reagents were in- 
cubated with Cls for 30 min at room temperature followed by over- 
night incubation with the substrates. After the incubation, samples 
were electrophoresed on 7.5% SDS-polyacrylamide gel (SDS-PAGE) 
under reducing conditions. Effects of Cls inhibitors were quantitated 
by densitometric scanning of the gel using Soft Laser Scanning Den- 
sitometer model SLR-ZD/lD (Biomed Instr., CA). 
2.4. Esterase assay 
The esterase activity of human Cls was measured by utilizing syn- 
thesized peptides, acetyl-Gly-L-Lys-naphthyl ester (AGLNE), as 
described [ll] with minor modifications. Human Cis (0.1 pg) and 
6.3 nmol of AGLNE, were incubated in 50~1 of 10 mM Tris-HCl 
buffer (pH 7.4) and 6.3 pl of 1% Fast violet B salt were added. The 
wine color developed was quantitated at 515 nm with a spec- 
trophotometer model DU-65 (Beckman lnstr., CA). 
Published by Eisevier Sctence Publishers B. V. (Biomedical Division) 
00145793/90/$3.50 0 1990 Federation of European Biochemical Societies 206 
Volume 268, number 1 FEBS LETTERS July 1990 
3. RESULTS AND DISCUSSION 1 23 45 67 
The cDNA encoding for CASP contains a 5 ’ non- 
coding region, 2085 nucleotides coding for a polypep- 
tide precursor of 695 amino acids containing 63 
nucleotides coding for a signal peptide and a 3 ’ non- 
coding region. The cDNA of human Cls consists of 
2064 nucleotides including 45 bases coding for a signal 
peptide. Homology of nucleotide sequences of coding 
regions between CASP and human Cls was 81 .O%, but 
homologies were detected neither at 3 ’ nor at 5 ’ un- 
translated regions (data not shown). The deduced 
amino acid sequence of CASP was compared with that 
of human Cls (Fig. 1). The leader sequence of CASP 
is 6 amino acids longer than that of human Cls. Both 
CASP and human Cls are cleaved between Arg and Be 
to be converted to active forms (Fig. 1, arrowhead). 
The heavy chains are highly homologous to each other 
(81.0%) including alignment of cysteine residues and 
mouse epidermal growth factor precursor domain. The 
light chains which contain the catalytic site of serine 
protease were less homologous than the heavy chain 
(68.3%). Particularly, there are several regions where 
distinct amino acids cluster near the active center. 
SSK- 
33K- 
Fig. 2. Degradation of type I and II collagen and gelatin by human 
Cls. Fivepg of type 1, II and gelatin were incubated with 1 ,BM of 
human Cls at 37°C overnight in 20 ,uI of 10 mM Tris-HCI buffer (pH 
7.4) containing 100 mM NaCl and 5 mM CaC12 followed by 
electrophoresis on 7.5% SDS-PAGE and Coomassie blue staining. 
Arrowheads show degradation products. (Lane 1) Human Cis; (lanes 
2,3) type I collagen; (lanes 4,5) type II collagen; (lanes 6,7) gelatin; 
(lanes 3,5,7) substrates with human Cls. 
In addition to a strong homology of cDNA between 
CASP and human Cls, they share similarities in 
biochemical and immunological properties. Those 
observations indicate that CASP is hamster Cls [7]. 
Therefore, we have examined if human Cls degrades 
extracellular matrix proteins which are hydrolyzed by 
1 MGKSSEAWCIVLFSVFASFSAEPTMHGEILSPNYPQAYPNEMEKTWDIEVPEGFGVRLYF 
1 M . . . . . . . LL.WVY . . . . . Y . . . . . . . . . . . . . S.V..S . . . . . . . . Y.IH... 
61 THLDMELSENCEYDSVQIISGGVEEGRLCGQRTSKNANSPIVEEFQIPYNKLQVIFRSDF 
55 . . ..I......A.........DT.........S.N.PH........V.........K... 
121 SNEERFTGFAAYYAAIDVNECTDFTDVPCSHFCNNFIGGYFCSCPPEYFLHDDMRNCGV~ 
115 . . . . . . . . . . . ..V.T.I......V.............................K..... 
181 CSGNVFTALIGEISSPNYPNPYPENSRCEYQILLEEGFQVVVTIQREDFDVEPADSQGNC 
175 . ..D.........A.....K............R..K.......LR.......A...A... 
241 QDSLLFAAKNRQFGPFCGNGFPGPLTIETHSNTLDIVFQTDLTEQKKGWKLRYHGDPIPC 
235 L...V.V.GD.....Y..H......N...K..A...I......G.............M.. 
301 PKEITANSVWAPEKAKYVFKDVVKISCVDGFEAVEGNVGSTFFYSTCQSNGQWSNSRLRC 
295 . ..D.P....E.A......R...Q.T.L....V...R..A.S.........K....K.K. 
361 QPVDCGIPEPIQNGKVDDPENTLFGSVIHYSCEEPYYYMEHAEHGGEYRCAA~GSWVNDE 
355 . . . . . . . ..S.E....E...S.......R.T.........NGG-....H..G......EV 
421 LGIELPKCVPVCGVPTEPFRIQQRIIFGGFPAKIQSFPWQVFFEFPRAGGALIGEHWVLTA 
414 ..P............R...EEK...I..SD.D.KN.......DN.W......N.Y..... 
481 A~VVEGNSDPSMYVGSTSVRMENLANVQKLTTDRVIIHPGWKPGDDLSTRTNFDN~IALV 
474 . . . . . ..RE.T........QTSR..KSKM..PEH.F......LLEVPEG........... 
541 RLKDPVKMGPTVSPICLPGTSSEYEPSEGDLGLISGWGRTERRNIVIQLRGAKLPVTSLE 
534 . . . . . . . . . . . . . . . . . . . . ..D.NLMD.............K.DRAVR.KA.R...AP.R 
601 KCRQVKEENPKARADOYVFTSNMICA-GEKGVOSCQGD~GGAFALPVPNVRDPKFYVAGL 
594 ..KE..V.K.T.D.EA....P.....G....M...K........VQD..DK-T...A... 
660 VSWGKKCGTYGIYTKVKNYKDWILQTMQENSVPSQD 
653 . . ..PQ.....L..R....V...MK......T.RE. 
Fig. 1. Homology of amino acid sequences between CASP and human Cls. * = identical residues; - = deletion; - = signal peptide; v = 
the cleavage site between heavy and light chain; * = the active sites of serine protease; = = sites of possible N-linked glycosylation. 
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Table I 
Effects of proteinase inhibitors and M241 on Cls activity 
Inhibitors Activity (Or0 control) 
Substrates: Collagen AGLNE 
Type I Type II 
No addition 
M241 
Mlg 
DFP 
EDTA 
Heat treatment 
100 100 100 
15.0 20.2 23.4 
92.1 89.4 187.6 
0 0.1 7.4 
113.9 103.4 78.6 
(56’C, 30 min) 2.2 ND* 0.9 
Type I or II collagen (5 pg) was incubated with human Cls (1 rg) 
with or without an inhibitor. M241 or mouse IgG (MIg) was added 
at the 1: 2 antibody/enzyme mol ratio, and DFP or EDTA was added 
at the concentration of 1 mM or 5 mM, respectively. M241 or MIg 
was used at the 5 : 1 antibody/enzyme mol ratio to examine the effect 
on the esterase activity. * ND, not done 
CASP [I]. Type I and II collagen and gelatin were 
shown to be degraded by human Cis (Fig. 2). There 
were several digestion products in the incubation mix- 
ture of Cis and type I collagen. Cis split type II col- 
lagen of mouse into two fragments of 2: 1 ratio in 
length. The same fragmentation was observed when 
type II collagen of chicken or monkey was used. Those 
were different from degradation products of typical 
type I or II collagenase [12]. Because the collagenases 
cleave collagen 75% and 25% in length and split Gly-Ile 
or Giy-Leu bond. On the other hand, Cls hydrolyzes 
the carboxyl-terming side of Lys, Arg or Tyr ]13-151. 
Unlike collagenases, the activity of Cls was completely 
blocked by a serine protease inhibitor, DFP, but not by 
EDTA (Table I). The monoclonal antibody, M241, in- 
hibited the esterase and collagenase activities. The 
esterase and proteinase activities were both heat labile. 
Different from CASP, human Cis did not require 
divalent cations nor did it degrade fibronectin or 
laminin (data not shown). Human Cis has been 
reported to hydrolyze tyrosine ester bond 113,141 
besides that of lysine and arginine. However, CASP did 
not hydrolyze tyrosine ester (11. These differences in 
substrate specificity might be caused by the differences 
in amino acid sequences between human and hamster 
Cls near the active center. 
Cls is known as a subcomponent of the first comple- 
ment, which reacts at the first step of classical comple- 
ment pathway. Recently, however, Hakan et al. 
reported that human Cis cleaved human major 
histocompatibility complex (MHC) class I antigen 
[ 16,171. They speculate that Cls might play an impor- 
tant role in the regulation of the immune response. The 
findings that Cls degraded type I and II collagen and 
that it was detected in chondrocytes of hyaline cartilage 
by immunohistochemical ssay, suggest hat Cls might 
participate in the metabolism in cartilage matrix. It is 
also very interesting to know if Cls is involved in 
pathogenesis of rheumatoid arthritis (RA). This 
possibility could be supported by the observation by 
Boisscer et al. who reported that the sera of patients 
suffering from RA showed higher titer of antibodies to 
denatured type II collagen than to native one [18). 
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